Autophagy and lysosomal function are important for protein homeostasis and their dysfunction have been associated with Alzheimer's disease (AD). Increased immunoreactivities of an important lysosomal protease, cathepsin D (Cat D), are evident in amyloid plaques and neurons in patients with AD. This study tests the hypothesis that deleting one allele of the cathepsin D gene (Ctsd) impacts cerebral b-amyloidosis in amyloid-b precursor protein (APP)sw/ PS1dE9 (APP/PS1) double transgenic mice. Despite a significant 38% decrease in Cat D level in APP/PS1/ Ctsd+/À compared with APP/PS1/Ctsd+/+ mice, no changes in steady state levels and deposition of Ab were found in the brain. There were also no differences in APP processing, the levels of two other Ab-degrading proteases, the levels of autophagy related protein, such as LAMP2, P62, LC3-I, LC3-II, and Beclin-1, or the markers of neuroinflammation, observed between the APP/PS1/Ctsd+/+ and APP/PS1/Ctsd+/À mice. Our findings demonstrate that in wild-type mice, Cat D protein levels are either in excess or redundant with other factors in the brain, and at least one allele of Ctsd is dispensable for cerebral b-amyloidosis and autophagy in APP/PS1 transgenic mice.
Background
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by deposition of b-amyloid (Ab) as senile plaques, formation of neurofibrillary tangles composed primarily of phosphorylated tau, and large-scale cortical neuronal loss leading to dementia (Goedert and Spillantini 2006) . Mounting evidence suggests that the autophagylysosome system is critical for the clearance of the misfolded proteins, and dysregulation of autophagy-lysosome system may be involved in the formation of amyloid plaques and tau aggregates which occurs in AD (Boland et al. 2008; Tizon et al. 2010; Lee et al. 2011; Yang et al. 2011 Yang et al. , 2014 Annunziata et al. 2013; Nixon 2013; Vilchez et al. 2014; Bordi et al. 2016; Colacurcio and Nixon 2016) .
Lysosomes play a major role in recycling damaged proteins and intracellular organelles through macroautophagy and chaperone-mediated autophagy. Such degradative functions critically depend on the cathepsin proteases (de Duve and Wattiaux 1966; Feng et al. 2014; Morimoto and Cuervo 2014; Zhang 2015) . Cathepsin D (Cat D) is a major lysosomal aspartic protease (Schneider and Zhang 2010) , synthesized as a prepropeptide (~53 kDa); with the signal peptide cleaved in the endoplasmic reticulum (~48 kDa), and further cleaved and activated in the lysosomes (~33 and~15 kDa) (Erickson and Blobel 1983) . Cat D is expressed widely in the mammalian brains (Furuta et al. 1999) , and is up-regulated in affected brain regions in AD; this up-regulation is accompanied by autophagic vesicle accumulation Cataldo et al. , 1991 Cataldo et al. , 1994 Cataldo et al. , 1995 Cataldo et al. , 1996 Cataldo et al. , 1997 Diedrich et al. 1991; Schwagerl et al. 1995; Callahan et al. 1999; Nixon et al. 2005; Yu et al. 2005) . In humans, Cat D deficiency causes congenital neuronal ceroid lipofuscinosis (Siintola et al. 2006; Steinfeld et al. 2006) . Cathepsin D gene (Ctsd) knockout mice die around post-natal day 26, with lethality caused by both systemic and nervous system defects including intestinal necrosis, seizures, neurodegeneration, and accumulation of protein aggregates (Saftig et al. 1995; Koike et al. 2000 Koike et al. , 2003 Koike et al. , 2005 Nakanishi et al. 2001; Shacka et al. 2007; Qiao et al. 2008; Cullen et al. 2009 ).
Expression of a dominant negative Cat D in SH-SY5Y cells led to decreased Cat D activities in these cells with accumulation of endogenous a-synuclein (Crabtree et al. 2014) . Partial loss of Cat D activity in Cat D haplodeficient SH-SY5Y cells resulted in a decrease in lysosomal function and increased cell-to-cell transmission of a-synuclein aggregates (Bae et al. 2015) . Haplodeficiency of Ctsd resulted in mania-related behavior and stress-induced depression (Zhou et al. 2015) , and a compensatory increase in striatal dopamine, while dopamine and metabolites were depleted to similar levels between Ctsd+/+ and Ctsd+/À mice in response to subchronic exposure to neurotoxin MPTP (Crabtree et al. 2013) .
In AD patients, increased Cat D in amyloid plaques and neurons were found, and it functions as a highly active endopeptidase Cataldo et al. , 1991 Cataldo et al. , 1994 Cataldo et al. , 1995 Cataldo et al. , 1996 Cataldo et al. , 1997 Diedrich et al. 1991) . Polymorphisms in the Cat D-encoding gene CTSD have been associated with AD (Papassotiropoulos et al. 2000; Beyer et al. 2005; Paz-y-Mino et al. 2015) . Potential mechanistic involvement of Cat D as the b-or c-secretase in the amyloidogenic processing of amyloid-b precursor protein (APP) has also been suggested (Ladror et al. 1994; Hamazaki 1996; Zhang et al. 2009 ).
Whether a decrease in this enzyme could affect Ab production or clearance was unclear (Saido and Leissring 2012; Leissring 2016) . To address this question, we crossed APPswe/PS1dE9 (APP/PS1) mice (Jankowsky et al. 2004 ), a well-established mouse model of AD, with Ctsd heterozygous knockout (Ctsd+/À) mice (Saftig et al. 1995) , and analyzed Ab deposition and levels of autophagy proteins at 6 months of age.
Methods
Animals APP/PS1 double transgenic mice (B6C3-Tg(APPswe, PSEN1dE9) 85Dbo/J; stock number 004462) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). These mice co-overexpress amyloid-b precursor protein (APP) with the Swedish double mutation (APPsw) and presenilin 1 (PS1) with deletion of exon 9 under the control of mouse prion promoter and breed like a single transgenic mouse line (Jankowsky et al. 2004) . Ctsd+/À heterozygous knockout mice were in C57BL/6 background. APP/PS1 mice were crossed with Ctsd+/À mice to generate APP/PS1/Ctsd+/À and APP/PS1/Ctsd+/+ littermate controls. Genotyping of the mice was performed with genespecific primers by PCR analysis of DNA extracts from tail biopsies. For this study, these mice were euthanized at 6 months of age for analysis of AD-related pathology. Mice of both sexes were used in this study. Age and sex-matched APP/PS1/Ctsd+/À and APP/PS1/Ctsd+/+ mice were analyzed. Littermates were used whenever possible. Experimentalists were blinded to the genotypes of the mice during the investigation to minimize potential bias. For each genotype, 8-9 mice (balanced sexes) were analyzed. Based on our published work with APP/PS1 mice (Cheng et al. 2013; Cheng et al. 2014) and power analysis (SigmaPlot13.0, Systat Software, San Jose, CA, USA), this experimental design allowed us to detect a difference of 25% between the two groups with 90% power at a = 0.05. All animal procedures were prospectively reviewed and approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham and the University of Minnesota. All efforts were made to minimize pain and distress.
Tissue isolation and preparation Ketamine (100 mg/kg) and xylazine (10 mg/kg) were intraperitoneally injected, and anesthesia was confirmed by the complete depression of palpebral and pedal reflexes. After blood was collected by cardiac puncture in the presence of anticoagulant heparin, cardiac perfusion with ice-cold phosphate-buffered saline was performed, the brains dissected, with the left hemisphere fixed in 4% paraformaldehyde for histological analysis, and the right hemisphere without cerebellum and brain stem snap frozen in liquid nitrogen and stored at À80°C for biochemical analysis.
Brain Ab ELISA and immunoblot analysis
We prepared brain homogenates as described previously (Cheng et al. 2013) . Ab 1-40 and Ab 1-42 levels in carbonate soluble and insoluble (guanidine soluble) fractions were measured using commercial ELISA kits (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. For western blot analysis, aliquots of brain homogenate were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidenedifluoride membranes. Primary antibodies against the carboxyl terminus of APP (CT695; Invitrogen), Cat D (sc-6486, Santa Cruz Biotechnology, Santa Cruz, CA, USA), insulindegrading enzyme (IDE) (PC730; EMD Biosciences/Millipore, Billerica, MA, USA), neprilysin (sc-9149; Santa Cruz Biotechnology), ionized calcium-binding adaptor molecule-1 (IBA-1) (Wako, Richmond, VA, USA), glial fibrillary acidic protein (GFAP) (Millipore), Beclin (sc-11427, Santa Cruz Biotechnology), lysosomeassociated membrane protein 2a (37024; Abcam, San Francisco, CA, USA), autophagic adapter protein sequestosome/p62 (Abnova, H00008878-M02), microtubule-associated protein I or II light chain 3 (LC3-I or LC3-II) (L8918; Sigma) were used, followed by horseradish peroxidaseconjugated secondary antibodies, and signals developed by using the ECL plus Western Blotting System (GE Healthcare, Pittsburgh, PA. USA). The blots were then stripped and reprobed with mouse anti-actin antibody (MAB1501R, Millipore and Sigma, A5441) or mouse anti-tubulin antibody (T5168; Sigma) as loading controls. Immunoreactive bands were then quantified by Image J software.
Immunohistochemical analysis and quantification of Ab deposition
We performed immunohistochemical analysis as described (Cheng et al. 2014) . The left hemispheres fixed with 4% paraformaldehyde were sectioned at 50 lm using a vibratome (Leica Microsystems Inc., Buffalo Grove, IL, USA), sections were stored at 4°C in phosphate-buffered saline with 0.01% sodium azide before subjected to freefloating immunostaining with primary antibody 6E10 (Covance, Princeton, NJ, USA) using the ABC kit (Vector, Burlingame, CA, USA) to detect Ab deposition. A histomorphometry system (Image-Pro Plus, Media Cybernetics, Rockville, MD, USA) was used to quantify immunoreactivity of Ab in the cortex and hippocampus.
Statistical analysis
Data are represented as means AE standard error of the mean (SEM). Comparison between the two different genotype groups was performed by the Student's t-test, with p < 0.05 considered statistically significant.
Results
Decreased Cat D levels in APP/PS1/Ctsd+/À mice compared with APP/PS1/Ctsd+/+ mice Breeding of APP/PS1 mice with Ctsd+/À mice produced mice that carry the APP/PS1 double transgenes and heterozygous deletion of the Ctsd gene. To verify the haplodeficiency of Ctsd gene results in decreased protein levels of Cat D in the brain, we performed western blot analyses in lysates of the mouse cortex at 6 months of age. As expected, the protein levels of Cat D, including the inactive precursor proenzyme (53 kDa), intermediate proenzyme (48 kDa), and non-covalently associated two-chain form (C-terminal 33-kDa heavy chain and N-terminal 15-kDa light chain), were decreased significantly by 38% in APP/PS1/Ctsd+/À mice compared with that in APP/PS1/ Ctsd+/+ littermate controls (Fig. 1) .
Ctsd haplodeficiency does not alter steady state levels and deposition of Ab in brains of APP/PS1 mice To assess the effect of haplodeficient Ctsd on amyloid plaque load in APP/PS1 mice, we performed a quantitative histologic analysis of amyloid plaques after staining with human Ab antibody (6E10). No significant differences in amyloid burden were found between the two groups of mice in both hippocampal and cortical regions (Fig. 2) . Consistent with Immunoblot of b-actin was used as a loading control. CtsdÀ/À P25 cortex extract was used as a negative control. (b) densitometric analysis of immunoblots (normalized by the amount of b-actin) with the levels in the APP/PS1/Ctsd+/+ group set as 100% (n = 8 per genotype; four males and four females). **p < 0.01. Bar = means AE SEM. these findings, there was no difference in the levels of Ab 1-40 and Ab 1-42 between the two groups, which was analyzed by ELISA and quantified both in the carbonate-soluble andinsoluble (guanidine-soluble) fractions in brain lysates (Fig. 3) .
Ctsd haplodeficiency does not affect APP processing in brains of APP/PS1 mice To determine whether Ctsd deficiency might alter APP expression or processing, we determined the steady-state levels of full-length APP (flAPP) and carboxyl-terminal fragments (CTFs) by immunoblot analyses. The results indicated that the level of APP was unaltered by decreasing the levels of Cat D (Fig. 4) . Furthermore, CTFa and CTFb of APP, produced by a-and b-secretase cleavages, respectively, and the ratios of CTFa to CTFb or the ratios of flAPP to CTFs also remained unchanged (Fig. 4) , indicating that Ctsd haplodeficiency does not affect APP processing.
Ctsd haplodeficiency does not influence the levels of two other Ab-degrading proteases or the markers of neuroinflammation in APP/PS1 mice As the net level of Ab is controlled by the balance between APP processing/Ab production and Ab clearance, we determined whether Ctsd haplodeficiency influence the levels of other Ab-degradation proteases in the brain. Two wellcharacterized Ab-degrading proteases, IDE and neprilysin (NEP) (Saido and Leissring 2012; Leissring 2016) , were examined by immunoblot analysis. The results showed that the levels of IDE and NEP were not different between APP/ PS1/Ctsd+/+ and APP/PS1/Ctsd+/À mice (Fig. 5) , indicating that Ctsd haplodeficiency does not influence the level of these two Ab-degradation proteases. Furthermore, we measured the markers of neuroinflammation, GFAP for activated astrocytes and ionized calcium-binding adaptor molecule-1) (IBA-1) for activated microglia. The results showed that there were no significant differences in the levels of GFAP and IBA-1 between APP/PS1/Ctsd+/+ and APP/PS1/Ctsd+/ À mice (Fig. 5) , indicating that Ctsd haplodeficiency does not affect the extent of neuroinflammation in APP/PS1 mice.
Ctsd haplodeficiency does not change autophagy related protein levels in APP/PS1 mice To determine whether Ctsd haplodeficiency affects the levels of autophagy proteins, we performed immunoblot analyses of lysosome-associated membrane protein 2a, P62, Beclin, LC3-I, and LC3-II in brain homogenates from APP/PS1/ Ctsd+/À mice and APP/PS1/Ctsd+/+ littermate controls. No significant differences were found between the two groups for these proteins (Fig. 6) , indicating that Ctsd haplodeficiency had no obvious effect on autophagy in the brain of APP/PS1 mice.
Discussion
Autophagy-lysosomal function is important for clearance of protein aggregates in cells. Our results showed that Ctsd haplodeficiency did not affect Ab levels and deposition, APP processing, the levels of two other Ab-degrading proteases, neuroinflammation, or autophagy in the brain of 6-month-old APP/PS1 mice, indicating that either Cat D is in excess or redundant with other factors for these functions.
The initial suggestion of Cat D in serving b or c-secretase activities used aspartyl protease inhibitor difluoro ketone peptidomimetic (Wolfe et al. 1999) . Purified Cat D has also been shown to hydrolyze Ab between amino acid Phe19 and Phe20 (Hamazaki 1996) , potentially as Ab-degrading enzyme. The involvement of Cat D in APP processing have been challenged by the study that Ctsd+/+ and CtsdÀ/À primary hippocampal neurons infected with recombinant Semliki Forest Virus expressing APPswe (K595N and M596L) and APPv642I mutation exhibited similar APP secretory processing, production of C-terminal fragments, and secretion of Ab, contradicting a potential role of Cat D in serving as an a-, b-or c-secretase (Saftig et al. 1996) . Nonetheless, Cat D has been found to be decreased in monocytes derived from patients with AD, which exhibited decreased ability to degrade Ab in vitro (Tian et al. 2014) . Inhibition of Cat D or RNAi-mediated knockdown of Cat D in THP-1 cells also decreased their abilities to clear amyloid plaques from APP/PS1 mouse brain sections (Tian et al. 2014) . Limitations of these studies include using cell cultures rather than directly observing APP metabolism and Ab burden in vivo. Our study demonstrated that in APP/PS1 mouse brain at 6 months of age, Cat D protein levels are directly correlated with gene dosage, i.e. Ctsd heterozygosity results in~38% decrease in Cat D protein level (Fig. 1) . Our results show for the first time that the levels of flAPP, CTFa, CTFb, which are regulated by secretases, were not changed significantly in Cat D deficient APP/PS1 mice. In addition, we showed that Ctsd haplodeficiency does not influence the level of two other well-established Ab degrading proteases, IDE and NEP, in the brain of APP/PS1 mice. Furthermore, there were no significant changes in the markers of neuroinflammation (GFAP and IBA-1) between APP/PS1/ Ctsd+/+ and APP/PS1/Ctsd+/À mice. As glial activation is associated with the deposition of Ab in APP/PS1 mice, the lack of changes in neuroinflammation is consistent with no change in Ab levels and plaque load in these mice. Taken together, these findings indicate that at least one allele of Ctsd is dispensible for amyloid production and degradation, as well as Ab-associated neuroinflammation, in the APP/PS1 mouse model in vivo.
Genetic inactivation of lysosomal Cat B (CtsbÀ/À) has been shown to increase Ab1-42, worsen AD-related pathologies in J20 hAPP mice and lentiviral delivery of Ctsb into hippocampus of J20 hAPP mice alleviates pathology (Mueller-Steiner et al. 2006) . There is a possibility that Cat B is more important than Cat D in attenuating AD-related pathology. However, further studies fully inhibiting Cat D activity rather than decreasing its level by 38%, and comparing Cat D and Cat B function in the same AD model will be necessary to compare and contrast the relative contribution of Cat D versus Cat B in APP/Ab metabolism and AD pathogenesis.
A number of studies have demonstrated an increase in Cat D in AD patient brain tissue and cerebrospinal fluid Cataldo et al. , 1991 Cataldo et al. , 1994 Cataldo et al. , 1995 Cataldo et al. , 1996 Cataldo et al. , 1997 Diedrich et al. 1991; Schwagerl et al. 1995; Callahan et al. 1999) , while a decrease in monocytes and fibroblasts (Urbanelli et al. 2008; Tian et al. 2014) . It was unclear whether Cat D in the brain or in non-brain organs/ tissue plays a detrimental, protective or bystander role in AD pathogenesis. Future studies that compare and contrast decreasing Cat D levels specifically in the central nervous system versus in monocytes and/or fibroblasts may help resolving this issue. Furthermore, specific up-regulation of Cat D levels in the central nervous system versus in monocytes and/or fibroblasts may also reveal whether more Cat D is detrimental or protective in AD pathogenesis. Analyzing whether Cat D loss of function or gain of function impacts AD pathogenesis in ApoE related, tau related or diabetes related models may also provide important information in disease mechanism-specific function of Cat D.
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